Tecnotree Recognized as Representative Vendor in Gartner Market Guide for CSP Customer Management and Experience Solutions
13.4.2023 13:46:00 EEST | Business Wire | Press release
Tecnotree, a global digital platform and services leader for 5G, IOT, and cloud-native technology, announced that it has been named as a representative vendor in the 2022 Gartner Market Guide for CSP Customer Management and Experience Solutions.
The Gartner report is authored by analysts Juha Korhonen, Amresh Nandan, Chris Meering, and Susan Welsh de Grimaldo. It focuses on two major components of Customer Management and Experience (CM&X) solutions, which benefit CSPs immensely. The Gartner market guide enables CSPs to understand market trends & sourcing strategies and keep up with the evolving CM&X solutions. It helps them transform themselves with advancing digital technologies, which further empowers them to manage different aspects of BSS (Business Support Systems), such as customers, services, products, and partners.
Tecnotree has been featured in Gartner for its complete range of CM&X solutions, which includes CRM solutions, self-care apps, product catalogue, customer management, customer journey orchestration, partner management, loyalty programs, Diwa Fintech platform, and for its multi-experience B2B2X ecosystem marketplace platform called Tecnotree Moments, which uses Azure and AWS cloud infrastructure with multitenant capabilities. The Surge, low/no-code platform provides intelligence-enabled customer experience and business orchestration capabilities that can be coupled with moments marketplace capabilities and core digital BSS functionality, that can drive IoT and 5G monetization and automation utilizing mutli-cloud technologies.
Tecnotree solutions assist customers on a BSS transformation journey from being a traditional Communications Services Provider (CSP) to a Digital Services Provider (DSP). With over 44 TM Forum Open APIs deployed for customer management, product and order management, partner management, rating & charging, billing and ecosystem management, Tecnotree helps in providing a complete Digital transformation as well as specific transformation related to customer experience and management. Tecnotree’s cloud-native, AI/ML enabled, and 5G-ready customer experience solutions include cutting-edge digital products. The Gartner report mentions that Tecnotree has implemented several of the TM Forum APIs for CM&X and is among the leading vendors in TM Forum Open APIs certification. The report further recognises the platform that employs a micro-services-based architecture with a unified product catalogue that facilitates customer onboarding, allows converged billing, launches multi-experience bundled offerings, and provides a 360-degree customer view through its patented “profile of one” technology.
‘We are pleased to be recognized in Gartner’s prestigious market guide for our CSP customer management and experience solutions for 2023 again in addition to the recognition that we already received for Revenue Management & Monetization in Q4 of 2022. Our AI-driven CSP solutions meet the rapidly evolving business needs and create 5G revenue opportunities for CSPs, enabling them to provide greater services across various functions. We offer our valued customers increased convenience and unlimited access to world-class products and solutions.’ said Padma Ravichander, CEO-Tecnotree.
She commented further, ‘Our consistent year-on-year inclusion in the Gartner market guide validates our position as being customer-focused in creating digital experiences and revolutionizing enterprise experience through ecosystem partnerships for new-age digital services in a consistent manner.’
About Tecnotree
Tecnotree is a 5G-ready digital Business Support System (BSS) player, with AI/ML capabilities and multi-cloud extensibility. Tecnotree is among the first companies in the world to be Platinum Certified by TM Forum Open API standards, and our agile and open-source Digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree is listed on Helsinki Nasdaq (TEM1V).
Gartner Disclaimer
Gartner does not endorse any vendor, product, or service depicted in our research publications and does not advise technology users to select only those vendors with the highest ratings or other designations. Gartner’s research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005460/en/
Contact information
Padma Ravichander, Tecnotree CEO
Email: marketing@tecnotree.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release
Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 08:09:00 EEST | Press release
LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through centers in Romania and Portugal. This would create a more diversified portfolio for LTM – expanding its scale in Europe and Australia, enhancing its position in regulated and high-growth verticals through marquee customer relationships. The deal would augment LTM’s global AI-centric capabilities with local domain and near-shore expertise crucial for delivering digital an
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 08:00:00 EEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
